1. Weir E, Fisman DN: Latent tuberculosis: revised treatment guidelines. CMAJ 169:937?938, 2003
2. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection?New York and Georgia, 2000. Morb Mortal Wkly Rep 50:289?291, 2001
3. Jasmer RM, Saukkonen JJ, Blumberg HM, et al. : Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: A multicenter clinical trial. Ann Intern Med 137:640?647, 2002
4. MMWR Update: Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for the treatment of latent infection?United States, 2003, Morb Mortal Wkly Rep, 52, 735?739, 2003
5. Lewis J, Zimmerman H: Drug-induced autoimmune liver disease. In Autoimmune Liver Diseases. Krawitt EL, Wiesner RH, Nishioka (eds). New York, Elsevier Science BV, 1998, pp 627?649